| Symbol
| GRIN1
| contributors: mct - updated : 21-10-2016
|
| HGNC name
| glutamate receptor, ionotropic, N-methyl D-aspartate 1
|
| HGNC id
| 4584
|
| corresponding disease(s)
|
MRD8
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
|
significantly increased in male patients with AD  | | constitutional
|
|
| --low
|
| |
decreased in postmortem brain from people with schizophrenia | |
| Susceptibility
|
to schizophrenia to infantile spasms responsive to to adrenocorticotropic hormone |
| Variant & Polymorphism
other
| polymorphism G1001C asssociated to allele T4197C and T5988C of GRIN2B increasing the risk of schizophrenia |
|
in homozygous carriers of the CTA haplotype was higher responsive to adrenocorticotropic hormone than that in heterozygous carriers and non-carriers |
| 
|
| Candidate gene
| torsion dystonia |
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| neurology | acquired | | |
| a potential therapeutic target for preventing white matter damage in a variety of diseases
| | obesity | | | |
| dorsal vagal complex GRIN2A, GRIN1 can a potential therapeutic target for obesity | | diabete | | | |
| dorsal vagal complex GRIN2A, GRIN1 can a potential therapeutic target for diabetes |
| | |
|
| CA1-specific Nmdar 1 knockout mice | |
GluN1 hypomorph mice exhibit wide-ranging behavioral alterations |